Cumberland Pharmaceuticals Inc.
CPIXAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| B. Riley | maintain | Buy | Dec 3, 2019 |
| B. Riley Securities | maintain | Buy | Dec 3, 2019 |
| B. Riley Securities | maintain | Buy | Nov 18, 2019 |
| B. Riley FBR | maintain | Buy | Nov 18, 2019 |
| B. Riley FBR | maintain | Buy | Aug 17, 2018 |
| B. Riley Securities | maintain | Buy | Aug 17, 2018 |
| B. Riley FBR | maintain | Buy | May 5, 2018 |
| B. Riley FBR | maintain | Buy | Apr 17, 2018 |
| B. Riley Securities | maintain | Buy | Apr 17, 2018 |
| UBS | maintain | Neutral | Apr 10, 2013 |
| UBS | maintain | Neutral | Nov 12, 2012 |
| Wells Fargo | downgrade | Outperform →Market Perform | Nov 9, 2012 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 4, 2026 | $-0.20 | $-0.13 | $166.5K | $8.5M |
| May 5, 2026 | $-0.13 | $-0.13 | $9.1M | $8.5M |
| Mar 3, 2026 | $-0.01 | $-0.13 | $13.7M | $8.5M |
| Nov 4, 2025 | $-0.06 | $-0.13 | $8.3M | $9.6M |
| Aug 5, 2025 | $0.02 | — | $10.8M | — |
| May 6, 2025 | $0.16 | $-0.01 | $11.7M | $12.2M |
| Mar 4, 2025 | $-0.02 | $-0.11 | $10.4M | $9.2M |
| Nov 7, 2024 | $-0.02 | $-0.13 | $9.1M | $8.6M |
News
LOS ANGELES--(BUSINESS WIRE)---- $CPIX--CPIX Investors Have Opportunity to Join Cumberland Pharmaceuticals Inc. Fraud Investigation with SBS Law.
Cumberland Pharmaceuticals (NASDAQ: CPIX - Get Free Report) and United-Guardian (NASDAQ: UG - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk. Insider and Institutional Ownership 15.5% of Cumberland Pharmaceuticals
NASHVILLE, Tenn., Nov. 3, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-focused biopharmaceutical company committed to developing new products for rare diseases, announced today that it will provide a company update with third quarter 2026 financial results after the market closes on Tuesday, Nov. 10, 2026.
Cumberland Pharmaceuticals Inc. (CPIX) Discusses Duchenne Cardiomyopathy NDA Submission and Product Development Strategy Prepared Remarks Transcript
Cumberland Pharmaceuticals NASDAQ: CPIX said it plans to begin a rolling New Drug Application submission for Dyscorban, its ifetroban candidate for cardiomyopathy associated with Duchenne muscular dystrophy, after the U.S. Food and Drug Administration granted the company's request for rolling review.
NASHVILLE, Tenn., Oct. 26, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), ("Cumberland" or the "Company") an innovation-focused biopharmaceutical company developing new products for rare diseases, today provided an update on its ifetroban product candidate in development as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy ("DMD").
Ifetroban was well tolerated in patients with systemic sclerosis NASHVILLE, Tenn., Oct. 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, announces top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for patients with systemic sclerosis ("SSc").
NASHVILLE, Tenn., Oct. 23, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, confirmed that it will provide an update on its ifetroban product candidate in development as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy ("DMD").
NASHVILLE, Tenn., Oct. 19, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, announced today that it will provide an update on its ifetroban product candidate in development as a potential treatment for the cardiomyopathy associated with Duchenne muscular dystrophy ("DMD").
Shares of Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX - Get Free Report) crossed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $5.62 and traded as high as $8.34. Cumberland Pharmaceuticals shares last traded at $7.94, with a volume of 76,217 shares. Analyst Upgrades and Downgrades Separately, Weiss
Cumberland Pharmaceuticals (NASDAQ: CPIX - Get Free Report) and ANI Pharmaceuticals (NASDAQ: ANIP - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation. Analyst Ratings This is a breakdown of
Cumberland Pharmaceuticals Inc. has transformed from a commercial-stage pharma to a pre-revenue, Phase 2-stage biotech focused on rare diseases. Recent $100M asset sale to Apotex funds operations and pipeline, with a special dividend paid to shareholders and four late-stage clinical programs retained. All pipeline assets are based on ifetroban, targeting high-value indications like DMD cardiomyopathy, cancer metastasis, systemic sclerosis, and IPF.
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX - Get Free Report) passed above its 200-day moving average during trading on Tuesday. The stock has a 200-day moving average of $4.87 and traded as high as $8.15. Cumberland Pharmaceuticals shares last traded at $7.96, with a volume of 79,334 shares traded. Analysts Set New Price Targets CPIX has